Navigation Links
SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
Date:8/7/2008

cs. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug discovery, development and commercialization, which include, without limitation, the potential failure of development candidates to advance through preclinical studies or demonstrate safety and efficacy in clinical testing. The results of early preclinical studies or clinical trials may not be predictive of future results, and the Company cannot provide any assurances that any of its compounds or development candidates will have favorable results in preclinical studies or future clinical trials. In addition, results may be affected by the failure to enter into new collaborations on any of its research and development programs in the event that the merger transaction is not consummated, competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, the scope and validity of patent protection for its products, and its ability to obtain additional funding to support its operations. For a discussion of these and other factors, please refer to the risk factors described in the Company's annual report on Form 10-K for the year ended December 31, 2007 and the Company's most recent quarterly report on Form 10-Q as well as subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and SGX undertakes no obligation to revise or update this press release to reflect events or circumstances af
'/>"/>
SOURCE SGX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
3. Memory Pharmaceuticals to Announce Second Quarter 2008 Results on Wednesday, August 13, 2008
4. Watson Pharmaceuticals Reports Second Quarter 2008 Results
5. Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
6. Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights
7. Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
8. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008
9. Kowa Company, Ltd. Acquires ProEthic Pharmaceuticals, Inc.
10. Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals
11. Anacor Pharmaceuticals Appoints Dr. Kurt Jarnagin Vice President of Biological Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 14, 2014 The largest international professional organization ... and therapeutic derivatives thereof has endorsed an educational ... about the challenges of adulterated herb and botanical ... The Society for Medicinal Plant and ...
(Date:1/14/2014)... January 14, 2014 iLab Solutions, the leader ... the new Director of Product Strategy. In this role, Michelle ... iLab sub-teams to guide in the development of iLab products. ... the maximum possible benefit to the scientific community by offering ...
(Date:1/14/2014)... Mass. , Jan. 14, 2014  RXi Pharmaceuticals ... discovering, developing and commercializing innovative therapies addressing major ... that it received the Notice of Allowance from ... its unique self-delivering RNAi compounds (sd-rxRNA®), for the ...
(Date:1/14/2014)... 2014   Kinaxis ®, provider of RapidResponse ®, a ... operations planning ( S&OP ) service, is proud to be ... will be held at the Hilton San Diego Bayfront, January ... Elisabeth Kaszas , Director of Supply Chain at Amgen, ...
Breaking Biology Technology:World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... 26 Duska Therapeutics,Inc. (OTC Bulletin Board: DSKA.OB) ... information is available via Standard & Poor,s,Corporation Records ... full,description of Duska Therapeutics is published in the ... securities manual for secondary,trading in approximately 38 states ...
... in 21st ... ... in gene expression analysis-based diagnostics, is pleased to,announce that the company ... Dutch Innovation Platform.,MammaPrint, a 70-gene signature diagnostic test that predicts high ...
... FREMONT, Calif., June 26 ValGenesis, Inc., ... solutions, announced,the worldwide availability of ValGenesis 2.0, ... scalable validation life cycle,management and automation product., ... software suite can,efficiently manage the entire validation ...
Cached Biology Technology:Duska Therapeutics Obtains Standard & Poor's Listing 2Agendia's MammaPrint(R) Receives Prestigious Award From Dutch Innovation Platform 2Agendia's MammaPrint(R) Receives Prestigious Award From Dutch Innovation Platform 3ValGenesis, Inc. Announces Worldwide Release of Validation Life Cycle Management System - ValGenesis 2.0 2ValGenesis, Inc. Announces Worldwide Release of Validation Life Cycle Management System - ValGenesis 2.0 3
(Date:4/23/2014)... 23, 2014 A biomedical engineer at the University ... technology to make blood transfusions safer. His work is ... Institutes of Health (NIH). , Blood transfusions save ... modern medicine,s absolute necessities. Without them, for instance, routine ... are perfect, however. There,s strong evidence that transfusions of ...
(Date:4/23/2014)... leading a 2 million Food Standards Agency (FSA) project ... and industry workers. , Norovirus outbreaks can rapidly ... batch of frozen strawberries infected 11,000 people in Germany, ... of which strains cause infection and which foods are ... , Researchers will produce data that will help the ...
(Date:4/22/2014)... are all sorts of signaling strategies in nature. Peacocks ... satin bowbirds build specialized stick structures, called bowers, and ... bitterling males show off bright nuptial coloration during spawning ... communicate with others. , ... fitness implications for individuals that are either signaling or ...
Breaking Biology News(10 mins):UH biomedical engineer works to make blood transfusions safer 2UH biomedical engineer works to make blood transfusions safer 3Best practices in communication for the animal world 2Best practices in communication for the animal world 3
... been elected to Fellowship in the American Academy ... annually through a highly selective, peer-review process, based ... contributions that have advanced microbiology. There are now ... including basic and applied research, teaching, public health, ...
... underrepresented in the applicant pool for faculty positions in math, ... apply are interviewed and hired at rates equal to or ... the National Research Council. Similarly, women are underrepresented among ... tenure at the same or higher rates than men. ...
... KNOXVILLE -- As swine flu spread from Mexico to Texas ... began to alter their behavior. Families kept children home from ... of eating out. In so doing, the American population may ... How human behavior changes the spread of emerging infectious diseases, ...
Cached Biology News:Seventy-three scientists elected to the American Academy of Microbiology 2Seventy-three scientists elected to the American Academy of Microbiology 3Seventy-three scientists elected to the American Academy of Microbiology 4Women faring well in hiring process for science faculty jobs at research universities 2Women faring well in hiring process for science faculty jobs at research universities 3Women faring well in hiring process for science faculty jobs at research universities 4Scientists examine human behavior and the threat of disease 2
Purified anti-mouse Tim-1...
Biotin d anti-mouse Tim-1...
Mouse monoclonal [1-N-14] to Adenovirus Type 7 hexon C11 Immunogen: Purified Adenovirus type 7 Specificity: This antibody is specific for Adenovirus type 7 hexon C11....
Request Info...
Biology Products: